Medical/Pharmaceuticals
Field Medical Names Mark A. Turco, MD, as Chief Executive Officer
CARDIFF-BY-THE-SEA, Calif., March 16, 2026 /PRNewswire/ -- Field Medical, Inc
2026-03-16 21:38
2767
Alar Announced Buprenorphine Injectable, ALA-1000, Demonstrated Long-Term Efficacy and Favorable Safety Profile in Canine Osteoarthritis Pain Management
* A study in client-owned dogs with osteoarthritis demonstrated that a single injection of ALA-1000 effectively mitigates pain and improves functional mobility, with a sustained drug release profile for at least 1 month. The study also confirmed a favorable safety profile with repeated use, par...
2026-03-16 20:00
2755
Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
* AVTOZMA® (tocilizumab-anoh) is among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations approved and commercially available inthe United States * The launch of AVTOZMA SC further diversifies Celltrion's immunology portfolio beyond TNF-alp...
2026-03-16 20:00
3551
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
Group Performance * Revenue: US$959.5 million, +61.4% year-on-year * Gross profit: US$553.2 million, +103.3% year-on-year * Adjusted net profit: US$230.3 million, +285.0% year-on-year Business Units' Performance * GenScript Life Science Group (LSG): US$522.1 million, +14.8% year-on-year ...
2026-03-16 18:54
4903
Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026 and Hold Online Earnings Call
SHANGHAI, March 16, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its financial re...
2026-03-16 17:58
3730
KLN Named Full-line Distributor for APT Medical's Coronary Intervention Products in Hong Kong
HONG KONG, March 16, 2026 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) is pleased to announce that its healthcare subsidiary, KLN Medical Limited ('KLN Medical'), is now the full-line distributor for APT Medical Inc.'s ('APT Medical'; Stock Code 688617.SH) coronary inte...
2026-03-16 12:05
2961
Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
HONG KONG, March 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has received Investigational New Drug (IND) clearance from the National Medical Products Administration (N...
2026-03-16 10:05
3324
Trial to test mild hyperbaric oxygen therapy during active treatment for aggressive brain cancer
LISMORE, Australia, March 15, 2026 /PRNewswire/ -- Australian researchers from Southern Cross University (SCU) and the Melbourne Integrative Oncology Group (MIOG) will launch a clinical study investigating whether hyperbaric oxygen therapy (HBOT) can safely support patients undergoing treatment f...
2026-03-16 09:43
2367
SUBANG JAYA MEDICAL CENTRE RANKED AMONG THE WORLD'S TOP 250 HOSPITALS AND TOP 10 REGIONALLY IN NEWSWEEK'S 2026 RANKING
KUALA LUMPUR, Malaysia, March 16, 2026 /PRNewswire/ -- Subang Jaya Medical Centre (SJMC) has been named among the Top 250 hospitals globally and top 10 regionally in Newsweek's World's Best Hospitals 2026, placing it among a select group of leading hospitals worldwide. The recognition highlights ...
2026-03-16 09:00
3018
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®[1], Floret...
2026-03-16 05:26
3241
Spring Into Healthy Breathing: Varon Offers Tips for Travel and Wellness with Oxygen Support
NEW YORK, March 15, 2026 /PRNewswire/ -- Spring is here, bringing warmer
weather, outdoor adventures, and family travel. For individuals who rely on
supplemental oxygen, enjoying the season safely requires preparation and the
right equipment. VARON
2026-03-15 14:03
3058
Vimgreen's Novel A2AR Antagonist Receives CDE IND Approval for NASH/MASH Therapy
HANGZHOU, China, March 14, 2026 /PRNewswire/ -- Vimgreen Pharmaceuticals, a leading innovator in adenosine signaling modulation, today announced the approval of its Investigational New Drug (IND) application for VG081821 in non‑alcoholic steatohepatitis (NASH), increasingly referred to as metabol...
2026-03-14 12:33
3921
Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics
* Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies * This partnership will generate revenue through: * A computational longevity platform, including unique curated datasets and accelerated computation methods releva...
2026-03-13 23:40
6357
Insilico Medicine to Announce 2025 Financial Results on March 30, 2026
CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Insilico Medicine (HKEX: 3696.HK, "Insilico" or the "Company"), a clinical-stage biotechnology company powered by generative artificial intelligence for drug discovery and development, today announced that it will report its financial results for t...
2026-03-13 21:59
8149
CityUHK researchers unveil the mystery of "Asian Flush" mechanism, pioneering new directions in precision treatment for heart attacks
HONG KONG, March 13, 2026 /PRNewswire/ -- Approximately 40% of the East Asian population suffers from alcohol intolerance, commonly known as "Asian Flush Syndrome". This ALDH2 genetic mutation is more than just a metabolic defect; it conceals a deadly cardiovascular risk. While the medical commu...
2026-03-13 21:30
5282
BioDlink Named "Emerging CDMO of the Year" at the 2026 Asia-Pacific Biopharma Excellence Awards
* BioDlink has been named "Emerging CDMO of the Year" for its innovation in complex biologics and ADC development. * The award recognizes its proprietary technology platforms, scalable manufacturing, and a proven quality system with over 100 audits completed. SUZHOU,China, March 13, 2026 /PRN...
2026-03-13 21:00
4956
Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy
SHANGHAI, March 13, 2026 /PRNewswire/ -- On March 12, Unixell Biotech achieved a significant milestone as UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This breakthro...
2026-03-13 20:06
3694
POMDOCTOR LIMITED Announces Strategic Upgrade, Focusing on "AI + Medical-Grade Smart Wearables" to Build a New Ecosystem for Full-Cycle Chronic Disease Management
GUANGZHOU, China, March 13, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases inChina, today announced a strategic upgrade centered on the core track of "artificial intelligence ("AI") + medical-gra...
2026-03-13 20:00
4035
Esaote at EAU 2026: Introducing Exclusive PAM Technology to Advance Precision in Urological Imaging
The technology is available on the new MyLab™E85 GTS Edition that will be showcased together with the brand new MyLab™C30 GTS ultrasound system at the Esaote booth LONDON, March 13, 2026 /PRNewswire/ -- Esaote Group, a leading Italian innovator in medical imaging - ultrasound, dedicated magnetic...
2026-03-13 19:00
3442
Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
* VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor * Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMD * VIS-101 demonstrated mean BVCA improvements of >10 ETDRS let...
2026-03-13 18:05
4329
Week's Top Stories
Most Reposted
Tetra Pak Opens Product Development Centre in Thailand, Unlocking A World of Possibilities for Food and Beverage Innovators Across Asia Pacific
[Picked up by 314 media titles]
2026-03-27 11:15
Visa Working Capital Index: Asia Pacific CFOs Call for Flexible, Digital Finance Solutions
[Picked up by 309 media titles]
2026-03-24 14:00Indonesia's P2P Lending Grows 25%, JULO Strengthens Credit Quality
[Picked up by 300 media titles]
2026-03-26 18:18
ART CENTRAL COMMENCES DISCOVERY-LED ELEVENTH EDITION
[Picked up by 277 media titles]
2026-03-25 16:51
RoboSense Beat Expectations, Achieved First-Ever Quarterly Profit on Strong Robotics Growth
[Picked up by 269 media titles]
2026-03-25 22:51